In addition to supportive transfusions, do you consider other interventions for symptomatic anemia and thrombocytopenia associated with chronic neutrophilic leukemia?  

Patient is 94 years old and not a candidate for intensive chemotherapy. Neutrophilia is controlled with low-dose hydroxyurea. She harbors a CSF3R mutation and is without significant splenomegaly. Is there any role for ESAs or TPO agonists in this setting?